# Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study

**Authors:** Zi-Rong Chen, Tsung-Yao Wan, Lan-Hsin Chuang, Chi-Chun Lai, Yih-Shiou Hwang, Yu-Kai Kuo, Ho-Min Chen, Po-Chun Chang, Hung-Chi Chen, Chun-Fu Liu

PMC · DOI: 10.1371/journal.pone.0327354 · PLOS One · 2025-08-07

## TL;DR

This study shows that early changes in eye length after atropine treatment can predict long-term eye growth in myopic children.

## Contribution

The study introduces a predictive model linking early axial length changes to long-term outcomes in children treated with 0.125% atropine.

## Key findings

- Early axial length elongation correlates with future axial elongation in children treated with 0.125% atropine.
- A turning point in axial length changes occurs at 67 days post-treatment.
- Initial 4-month axial length changes predict 6- and 12-month outcomes.

## Abstract

This study aimed to investigate whether early axial length (AL) changes in the short term after 0.125% atropine treatment could predict long-term axial elongation in children with myopia.

This was a prospective cohort study involving children aged 5–15 years with myopia who were treated with 0.125% atropine for myopia control. AL was measured 1–2 months after starting treatment and then every 3 months for follow-up visits. Regression analysis was used to develop a model of AL changes with time. A generalized estimating equation (GEE) model was then used to identify correlations between the early AL changes and long-term AL changes.

Eighty eyes of 40 patients (mean age 8.4 years) were included in the final analysis. The estimation curve of AL changes with time indicated that the AL decreased at 67 days (the turning point in the regression model) after 0.125% atropine treatment and then increased gradually with time. Univariate GEE showed that a larger AL elongation in the initial 4 months was significantly associated with AL changes at 6 months (β = 0.354, P = 0.020, 6 ~ 12 months period from baseline) and 12 months (β = 0.560, P = 0.045, 6 ~ 18 months period from baseline) after that period in all myopic eyes.

The magnitude of AL elongation in the initial 4 months of 0.125% atropine treatment correlated positively with the further half-year and one-year AL changes. Identifying these changes may be useful for controlling refractory myopia in children.

## Linked entities

- **Chemicals:** atropine (PubChem CID 3661)
- **Diseases:** myopia (MONDO:0001384)

## Full-text entities

- **Diseases:** Myopia (MESH:D009216), axial elongation (MESH:C537791)
- **Chemicals:** atropine (MESH:D001285)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12331118/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12331118/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12331118/full.md

---
Source: https://tomesphere.com/paper/PMC12331118